Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Lacrimal Apparatus Diseases 1Lacerations 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endophthalmitis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lubricant Eye Drops × Gastrointestinal × Clear all
NCT00824811 2012-08-02

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

M.D. Anderson Cancer Center

Phase 2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Lacrimal Apparatus Diseases, Lung Neoplasms, Endophthalmitis, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Lacerations, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡